Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus daratumumab and dexamethasone with or without bortezomib in relapsed or refractory multiple myeloma
jRCT2031200392Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of venetoclax, daratumumab, dexamethasone and bortezomib in multiple myeloma (MM) (7 arms), sponsored by AbbVie Inc. Primary endpoints: Overall Response Rate, Very Good Partial Response or Better Response Rate and 6 more. Started Nov 2021; status: active, not recruiting.
02
Drugs
venetoclaxdaratumumabdexamethasonebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031200392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200392.